The price of Guardant Health Inc. (NASDAQ: GH) closed at $28.61 in the last session, down -3.96% from day before closing price of $29.79. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 5215503 shares were traded. GH stock price reached its highest trading level at $29.97 during the session, while it also had its lowest trading level at $27.92.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
We take a closer look at GH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.40.
Upgrades & Downgrades
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 15 when Eltoukhy Helmy bought 8,600 shares for $26.15 per share. The transaction valued at 224,928 led to the insider holds 2,049,238 shares of the business.
Eltoukhy Helmy bought 84,452 shares of GH for $2,223,908 on Mar 14. The Co-Chief Executive Officer now owns 2,040,638 shares after completing the transaction at $26.33 per share. On Mar 14, another insider, Talasaz AmirAli, who serves as the Co-Chief Executive Officer of the company, bought 8,500 shares for $26.40 each. As a result, the insider paid 224,376 and bolstered with 24,250 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.71B and an Enterprise Value of 3.14B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.99. Its current Enterprise Value per Revenue stands at 6.51 whereas that against EBITDA is -5.05.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $62.75, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 25.05, while the 200-Day Moving Average is calculated to be 37.94.
According to the various share statistics, GH traded on average about 1.94M shares per day over the past 3-months and 2.8M shares per day over the past 10 days. A total of 102.66M shares are outstanding, with a floating share count of 97.63M. Insiders hold about 0.10% of the company’s shares, while institutions hold 94.00% stake in the company. Shares short for GH as of Apr 27, 2023 were 6.39M with a Short Ratio of 6.39M, compared to 6.76M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.22% and a Short% of Float of 6.53%.
The company has 16 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.2 for the current quarter, with a high estimate of -$0.72 and a low estimate of -$1.38, while EPS last year was -$2.25. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.79 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$3.47 and -$5.15 for the fiscal current year, implying an average EPS of -$4.65. EPS for the following year is -$3.96, with 16 analysts recommending between -$2.35 and -$5.32.
According to 17 analysts, the current quarter’s revenue is expected to be $129.28M. It ranges from a high estimate of $132.9M to a low estimate of $122.6M. As of the current estimate, Guardant Health Inc.’s year-ago sales were $109.14M, an estimated increase of 18.40% from the year-ago figure. For the next quarter, 17 analysts are estimating revenue of $136.04M, an increase of 15.50% less than the figure of $18.40% in the same quarter last year. There is a high estimate of $138.85M for the next quarter, whereas the lowest estimate is $133.71M.
A total of 19 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $545M, while the lowest revenue estimate was $538M, resulting in an average revenue estimate of $541.32M. In the same quarter a year ago, actual revenue was $449.54M, up 20.40% from the average estimate. Based on 19 analysts’ estimates, the company’s revenue will be $668.64M in the next fiscal year. The high estimate is $709.7M and the low estimate is $625M. The average revenue growth estimate for next year is up 23.50% from the average revenue estimate for this year.